VectorY Therapeutics has announced that the US Food and Drug Administration has granted Fast Track Designation to VTx-002, a first-in-class vectorised antibody therapy targeting TDP-43 pathology in amyotrophic lateral sclerosis. The designation is intended to accelerate development of treatments for serious conditions with high unmet medical need and supports the continued clinical advancement of the programme.
VTx-002 is designed to target abnormal TDP-43 protein aggregation, which is believed to drive disease pathology in up to 97 percent of ALS cases. The therapy uses a vectorised antibody approach, enabling sustained delivery within the central nervous system. VectorY states that this strategy aims to address the underlying disease biology rather than providing symptomatic benefit alone.
The Fast Track designation follows clearance of the investigational new drug application for VTx-002 in December 2025. This regulatory milestone allows the company to proceed with its planned PIONEER-ALS Phase 1/2 clinical study, which will evaluate the safety, tolerability and pharmacodynamic activity of the therapy in people living with ALS. The first patient is expected to be enrolled in early 2026.
Fast Track designation is intended to facilitate closer interaction between the FDA and drug developers during clinical development. Therapies granted this status may be eligible for more frequent regulatory meetings and, if appropriate, future consideration for Priority Review. The designation reflects both the severity of ALS and the lack of effective disease-modifying treatments currently available.
| Sign up to the ACNR email newsletter here |
VectorY Therapeutics is developing a pipeline of vectorised antibody therapies targeting key disease mechanisms across several neurodegenerative disorders. In addition to VTx-002, its portfolio includes programmes in ALS, Huntington’s disease, Alzheimer’s disease and frontotemporal dementia, reflecting a broader strategy to deliver durable, precision-targeted treatments for neurological disease.
This news item has been summarised using AI and checked by humans before publication.
Sources
Business Wire
| Sign up for our online community for neurology specialists |
